Your session is about to expire
← Back to Search
Not Applicable
Apollo System for ADHD
N/A
Waitlist Available
Led By Matthew B Pontifex, PhD.
Research Sponsored by Michigan State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must be 8 years of age or older and under the age of 18
Participants must have diagnosed or suspected Attention Deficit Hyperactivity Disorder (ADHD)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prior to and following the 8 week study protocol period.
Summary
This trial is testing the Apollo System, a device that uses vibrations to help balance the body's nervous system. It is aimed at children with ADHD to see if it can help them focus and control their behavior better. The study will compare the effects of the device.
Who is the study for?
This trial is for children aged 8-18 with ADHD who have had minimal relief from current treatments, tried multiple treatments without meeting goals, still experience symptoms on medication, or suffer from medication side effects. It's open to all genders and ethnicities.
What is being tested?
The Apollo System is being tested over an 8-week period at home to see if it can reduce ADHD symptoms in children who meet the study criteria.
What are the potential side effects?
The information provided does not specify side effects of the Apollo System. Typically, clinical trials monitor participants for any adverse reactions during the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 8 and 17 years old.
Select...
I have been diagnosed with or suspected to have ADHD.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ prior to and following the 8 week study protocol period.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prior to and following the 8 week study protocol period.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in ADHD symptomatology as assessed using the ADHD-5 Rating Scale
Effect Size for Change in Behavioral Index of Interference Control
Effect Size for Change in Behavioral Index of Response Inhibition
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Commercial Apollo System DeviceExperimental Treatment1 Intervention
The active experimental group received the commercial Apollo System device.
Group II: Sham Apollo System DevicePlacebo Group1 Intervention
The control experimental group received a sham/placebo device that is identical to the commercial Apollo System device but uses an ultra-low (i.e., effectively zero) frequency pattern of vibrations.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for ADHD are stimulant medications such as methylphenidate and amphetamines, which work by increasing the levels of dopamine and norepinephrine in the brain, thereby enhancing attention and reducing hyperactive and impulsive behaviors. Non-stimulant medications like atomoxetine increase norepinephrine levels by inhibiting its reuptake.
These mechanisms are crucial for ADHD patients as they help to normalize brain activity associated with attention and behavior control. The Apollo System, a wearable device delivering gentle vibrations to influence the autonomic nervous system, represents a novel approach by potentially modulating stress and improving focus through non-pharmacological means.
Enhancing attention in neurodegenerative diseases: current therapies and future directions.Attention-deficit/hyperactivity disorder and complementary/alternative medicine.
Enhancing attention in neurodegenerative diseases: current therapies and future directions.Attention-deficit/hyperactivity disorder and complementary/alternative medicine.
Find a Location
Who is running the clinical trial?
The Board of MedicineUNKNOWN
3 Previous Clinical Trials
700 Total Patients Enrolled
Michigan State UniversityLead Sponsor
198 Previous Clinical Trials
685,634 Total Patients Enrolled
Matthew B Pontifex, PhD.Principal InvestigatorMichigan State University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with or suspected to have ADHD.I am between 8 and 17 years old.I've tried multiple treatments for over a year with little relief or have uncontrollable side effects.I have not started any new treatments in the last 30 days.My eligibility is not affected by my sex, race, or ethnicity.I have agreed to participate and understand it's first come, first serve.I have been diagnosed with or suspected to have ADHD.My current treatment hasn't significantly improved my symptoms or has caused severe side effects.I am between 8 and 17 years old.You need to have normal or corrected-to-normal vision to complete the cognitive task.
Research Study Groups:
This trial has the following groups:- Group 1: Commercial Apollo System Device
- Group 2: Sham Apollo System Device
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT05308706 — N/A